GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Revolution Medicines RVMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

159.43

-0.24%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Revolution Medicines — daily RVMD Delayed
Market value
$30.82bn
Last close × shares
Volume
3.4m
Shares, 19 Nov 2026

About Revolution Medicines

From its filings with the US Securities and Exchange Commission

SEC filings

Revolution Medicines is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RVMD. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $1.13bn. At that date it held total assets of $2.35bn and shareholders' equity of $1.63bn.

In its own words

We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

We believe tailored RAS(ON) Inhibitors will be useful to serve the diverse landscape of RAS-addicted cancers optimally. In some cases, patients may experience maximal clinical benefit from the broad activity of a RAS(ON) multi-selective inhibitor, such as daraxonrasib (RMC-6236), which is designed to inhibit multiple oncogenic RAS variants. In other settings, treatment with a RAS(ON) mutant-selective inhibitor, designed to selectively target a specific RAS mutation, may be optimal. We further believe that in some cases, it could be beneficial to combine daraxonrasib with a RAS(ON) mutant-selective inhibitor, with daraxonrasib functioning as the backbone of these RAS(ON) Inhibitor doublets.

Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗

More about Revolution Medicines →

How it makes its money

Revenue, year to 31 Dec 2022

  • Collaboration revenue member. $35.4m · 100.0%

Latest on Revolution Medicines

Our reporting

Next results

24 Feb 2027

Due on 24 Feb 2027. Analysts expect earnings of -1.16 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Revolution Medicines's ticker?

Revolution Medicines trades as RVMD on its US listing, under ISIN US76155X1000.

What was Revolution Medicines's last closing price?

159.43 on 19 Nov 2026. The figure is in USD and is never converted.

When does Revolution Medicines next report results?

Results are expected on 24 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.